Dapiglutide Shows Promise in Phase 1b Trial for Overweight and Obesity Treatment
Monday, 9 September 2024, 15:50
Positive Outcomes From Dapiglutide's Phase 1b Trial
Zealand Pharma A/S (ZLDPF.PK) revealed promising topline results from their recent Phase 1b multiple ascending dose trial of dapiglutide, a long-acting GLP-1/GLP-2 receptor dual agonist. The trial, focusing on overweight and obesity treatment, has garnered attention for its positive outcomes.
Significant Weight Loss Documented
- The trial spanned 13 weeks, with participants on dapiglutide treatment demonstrating a mean body weight reduction.
- This breakthrough signifies a potential new avenue in tackling obesity through innovative receptor targeting.
- Participants showed compliance and marked effectiveness after continuous administration of the medication.
These results not only reflect the effectiveness of dapiglutide but also ignite expectations for future studies exploring its long-term impacts and safety profiles.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.